# Expert Review of Anticancer Therapy

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/expert-review-of-anticancer-therapy/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 1473-7140 |
| ISSNs | 1473-7140,1744-8328 |
| OpenAlex ID | https://openalex.org/S93370067 |
| Publisher | Taylor & Francis |

## Journal papers

- [Current and future therapeutic approaches for osteosarcoma](https://scholariq.org/papers/current-and-future-therapeutic-approaches-for-osteosarcoma/)
- [Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles](https://scholariq.org/papers/platinum-based-chemotherapy-in-advanced-non-small-cell-lung-cancer-optimal/)
- [MYC in breast tumor progression](https://scholariq.org/papers/myc-in-breast-tumor-progression/)
- [Epidemiology and treatment patterns of epithelial ovarian cancer](https://scholariq.org/papers/epidemiology-and-treatment-patterns-of-epithelial-ovarian-cancer/)
- [Desmoid tumors: need for an individualized approach](https://scholariq.org/papers/desmoid-tumors-need-for-an-individualized-approach/)
- [Laparoscopic nephrectomy for Wilms’ tumor](https://scholariq.org/papers/laparoscopic-nephrectomy-for-wilms-tumor/)
- [Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects](https://scholariq.org/papers/combination-therapies-for-the-treatment-of-her2-positive-breast-cancer-current/)
- [Lenvatinib as a therapy for unresectable hepatocellular carcinoma](https://scholariq.org/papers/lenvatinib-as-a-therapy-for-unresectable-hepatocellular-carcinoma/)
- [Imaging of the pituitary and sella turcica](https://scholariq.org/papers/imaging-of-the-pituitary-and-sella-turcica/)
- [Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma](https://scholariq.org/papers/increased-risk-of-arterial-thromboembolic-events-with-combination-lenalidomide/)
- [Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance](https://scholariq.org/papers/immunotherapy-based-therapy-as-a-promising-treatment-for-egfr-mutant-advanced/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.